| ipilimumab based treatment | ipilimumab alone | ipilimumab based treatment | anti-CTLA-4 | atezolizumab based treatment | nivolumab based treatment | anti-PD-(L)1 | pembrolizumab based treatment | pembrolizumab alone | pembrolizumab based treatment | Immune checkpoint association |
| ipilimumab alone | Ipilimumab (10 mg/kg) | ipilimumab plus gp100 | ipilimumab plus SoC | tremelimumab | atezolizumab plus cometinib | atezolizumab plus SoC | nivolumab alone | nivolumab followed by ipilimumab | pembrolizumab alone | pembrolizumab (10mg/kg) | pembrolizumab (10mg/kg) 2 weeks | pembrolizumab (2mg/kg) | pembrolizumab plus SoC | nivolumab plus ipilimumab | relatlimab plus nivolumab |
mML - (neo)adjuvant (NA) | | | | | | | | | | | | | | | | |
mML - NA - all population 9 | | | | | | | | | | | | | | | | |
mML - NA - PDL1 positive 1 | | | | | | | | | | | | | | | | |
mML - 1st line (L1) | | | | | | | | | | | | | | | | |
mML - L1 - all population 7 | | | | | | | | | | | | | | | | |
mML - L1 - BRAF mutant 2 | | | | | | | | | | | | | | | | |
mML - L1 - BRAF wild 3 | | | | | | | | | | | | | | | | |
mML - 2nd line (L2) | | | | | | | | | | | | | | | | |
mML - L2 - all population 11 | | | | | | | | | | | | | | | | |
mML - L2 - BRAF mutant 1 | | | | | | | | | | | | | | | | |